Strong HIV-Specific CD4 + and CD8 + T-Lymphocyte Proliferative Responses in Healthy Individuals Immunized with an HIV-1 DNA Vaccine and Boosted with Recombinant Modified Vaccinia Virus Ankara Expressing HIV-1 Genes
- 1 July 2010
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 17 (7) , 1124-1131
Abstract
We investigated HIV-1 vaccine-induced lymphoproliferative responses in healthy volunteers immunized intradermally or intramuscularly (with or without adjuvant granulocyte-macrophage colony-stimulating factor [GM-CSF] protein) with DNA expressing HIV-1 gag , env , rev , and rt at months 0, 1, and 3 using a Biojector and boosted at 9 months with modified vaccinia virus Ankara (MVA) expressing heterologous HIV-1 gag , env , and pol (HIV-MVA). Lymphoproliferative responses to aldrithiol-2 (AT-2)-inactivated-HIV-1 antigen were tested by a [ 3 H]thymidine uptake assay and a flow-cytometric assay of specific cell-mediated immune response in activated whole blood (FASCIA-WB) 2 weeks after the HIV-MVA boost ( n = 38). A FASCIA using peripheral blood mononuclear cells (FASCIA-PBMC) was also employed ( n = 14). Thirty-five of 38 (92%) vaccinees were reactive by the [ 3 H]thymidine uptake assay. Thirty-two of 38 (84%) vaccinees were reactive by the CD4 + T-cell FASCIA-WB, and 7 of 38 (18%) also exhibited CD8 + T-cell responses. There was strong correlation between the proliferative responses measured by the [ 3 H]thymidine uptake assay and CD4 + T-cell FASCIA-WB ( r = 0.68; P < 0.01). Fourteen vaccinees were analyzed using all three assays. Ten of 14 (71%) and 11/14 (79%) demonstrated CD4 + T-cell responses in FASCIA-WB and FASCIA-PBMC, respectively. CD8 + T-cell reactivity was observed in 3/14 (21%) and 7/14 (50%) using the FASCIA-WB and FASCIA-PBMC, respectively. All 14 were reactive by the [ 3 H]thymidine uptake assay. The overall HIV-specific T-cell proliferative response in the vaccinees employing any of the assays was 100% (38/38). A standardized FASCIA-PBMC, which allows simultaneous phenotyping, may be an option to the [ 3 H]thymidine uptake assay for assessment of vaccine-induced T-cell proliferation, especially in isotope-restricted settings.Keywords
This publication has 26 references indexed in Scilit:
- Broad Immunogenicity of a Multigene, Multiclade HIV‐1 DNA Vaccine Boosted with Heterologous HIV‐1 Recombinant Modified Vaccinia Virus AnkaraThe Journal of Infectious Diseases, 2008
- HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workersAIDS, 2008
- An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responsesJournal of Experimental Medicine, 2008
- Evaluation of Aldrithiol-2-Inactivated Preparations of HIV Type 1 Subtypes A, B, and D as Reagents to Monitor T Cell ResponsesAIDS Research and Human Retroviruses, 2007
- Proliferative Capacity of Epitope-Specific CD8 T-Cell Responses Is Inversely Related to Viral Load in Chronic Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2007
- Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+T-Cell EpitopesJournal of Virology, 2006
- Carboxyfluorescein succinimidyl ester‐based proliferative assays for assessment of T cell function in the diagnostic laboratoryImmunology & Cell Biology, 1999
- Correlation between DNA Content, Expression of Ki-67 Antigen of Tumor Cells and Immunophenotype of Lymphocytes from Malignant Pleural EffusionsTumor Biology, 1998
- Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infectionEuropean Journal of Immunology, 1991
- New anti-HIV-1 therapies and combinationsAIDS, 1990